Rein Therapeutics Inc. (NASDAQ:RNTX) Given Consensus Rating of “Hold” by Brokerages

Shares of Rein Therapeutics Inc. (NASDAQ:RNTX) have earned a consensus recommendation of “Hold” from the four research firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $6.00.

Several equities research analysts recently issued reports on RNTX shares. Maxim Group began coverage on Rein Therapeutics in a research note on Monday, July 20th. They set a “buy” rating and a $4.00 price objective for the company. HC Wainwright decreased their target price on Rein Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Monday, June 1st. Wall Street Zen raised Rein Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. Finally, Weiss Ratings upgraded Rein Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, August 3rd.

Institutional Investors Weigh In On Rein Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Susquehanna International Group LLP purchased a new position in Rein Therapeutics in the 3rd quarter worth approximately $35,000. HRT Financial LP bought a new position in shares of Rein Therapeutics in the 4th quarter worth $38,000. Chicago Partners Investment Group LLC raised its position in shares of Rein Therapeutics by 32.2% during the 1st quarter. Chicago Partners Investment Group LLC now owns 41,048 shares of the company’s stock valued at $53,000 after buying an additional 10,000 shares in the last quarter. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Rein Therapeutics during the 2nd quarter valued at $68,000. Finally, Jane Street Group LLC bought a new stake in shares of Rein Therapeutics during the 4th quarter worth $72,000. 90.89% of the stock is owned by hedge funds and other institutional investors.

Rein Therapeutics Price Performance

Shares of NASDAQ:RNTX opened at $0.79 on Friday. The firm has a fifty day moving average price of $0.89 and a two-hundred day moving average price of $1.14. Rein Therapeutics has a one year low of $0.69 and a one year high of $2.18. The company has a market cap of $67.36 million, a price-to-earnings ratio of -0.41 and a beta of 1.39.

Rein Therapeutics (NASDAQ:RNTX) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.30. Equities research analysts expect that Rein Therapeutics will post -0.53 EPS for the current fiscal year.

Rein Therapeutics Company Profile

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.